Osivax announces publication in The Lancet Infectious Diseases of Phase 2a data for broad-spectrum influenza vaccine candidate, OVX836
OVX836 demonstrated positive safety and immunogenicity data across three dose levels
A notable signal of protection of 84% was observed against symptomatic influenza infection
Lyon, France – July 28, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company’s OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebo-controlled, Phase 2a trial.” ...













